Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96MU7
UPID:
YTDC1_HUMAN
Alternative names:
Splicing factor YT521
Alternative UPACC:
Q96MU7; Q4W5Q3; Q7Z622; Q8TF35
Background:
YTH domain-containing protein 1, also known as Splicing factor YT521, plays a pivotal role in RNA metabolism. It specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, influencing mRNA splicing, processing, and stability. This protein is a key regulator of alternative splicing, interacting with mRNA splicing factors SRSF3 and SRSF10 to modulate exon-inclusion or exon-skipping. Additionally, it is involved in the nuclear export of m6A-containing mRNAs and plays a role in S-adenosyl-L-methionine homeostasis and random X inactivation mediated by Xist RNA.
Therapeutic significance:
Understanding the role of YTH domain-containing protein 1 could open doors to potential therapeutic strategies.